

## **Appendix 1 (as supplied by authors): Statements of competing interests by FRAX developers in published articles**

Competing interests declared by Professors Kanis and McCloskey in a recent review:<sup>1</sup>

“Disclosure of funding: No specific conflicts of interest for this manuscript. E. McCloskey: Speaker fees, advisory board and unrestricted research grants from Amgen, Bayer, Hologic, Lilly, Merck, Novartis, Pfizer, Procter & Gamble Pharmaceuticals, Roche, Sanofi Aventis, Servier and Tethys. J.A. Kanis: Consulting fees, paid advisory boards, lecture fees, and grant support from the majority of companies concerned with skeletal metabolism.”

Professor Kanis declared the following competing interests in a 2010 *CMAJ* commentary:<sup>2</sup>

Dr. Kanis has served as a consultant to Abiogen, Italy; Amgen, USA, Switzerland and Belgium; Bayer, Germany; Besins-Iscovesco, France; Biosintetica, Brazil; Boehringer Ingelheim, UK; Celtrix, USA; D3A, France; the European Federation of Pharmaceutical Industries and Associations; Gador, Argentina; General Electric, USA; GSK, UK and USA; Hologic, Belgium and USA; Kissei, Japan; Leo Pharma, Denmark; Lilly, USA, Canada, Japan, Australia and UK; Merck Research Labs, USA; Merlin Ventures, UK; MRL, China; Novartis, Switzerland and USA; Novo Nordisk, Denmark; Nycomed, Norway; Ono, UK and Japan; Organon, Holland; Parke-Davis, USA; Pfizer, USA; Pharmexa, Denmark; Procter and Gamble, UK and USA; ProStrakan, UK; Roche, Germany, Australia, Switzerland and USA; Rotta Research, Italy; Sanofi-Aventis, USA; Schering, Germany and Finland. He has provided expert testimony for the High Court (UK). His institution has received grants from the Medical Research Council (UK), the Arthritis and Rheumatism Council (UK) and the European Federation of Pharmaceutical Industries and Associations. He has received speaker’s fees from Amgen, Novartis and Servier. He has also worked with the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, the Government of Manitoba, the Group for the Respect of Ethics and Excellence in Science, INSERM (France), the Medical Research Council (UK), the Ministry of Public Health of China, the Ministry of Health of Australia, the National Institute for Health and Clinical Excellence (UK), the National Osteoporosis Guideline Group (UK), the National Osteoporosis Society (UK), the International Osteoporosis Foundation, the Japanese Osteoporosis Society, Osteoporosis 2000 (UK), Osteoporosis Australia, the Swiss Osteoporosis Society and the WHO.

### **References**

1. McCloskey E, Kanis JA. FRAX updates 2012. *Curr Opin Rheumatol* 2012;24:554-60.
2. Kanis JA. New osteoporosis guidelines for Canada [commentary]. *CMAJ* 2010;182:1829-30.